110 related articles for article (PubMed ID: 15103390)
1. MEIS 1 expression is downregulated through promoter hypermethylation in AML1-ETO acute myeloid leukemias.
Lasa A; Carnicer MJ; Aventín A; Estivill C; Brunet S; Sierra J; Nomdedéu JF
Leukemia; 2004 Jul; 18(7):1231-7. PubMed ID: 15103390
[TBL] [Abstract][Full Text] [Related]
2. Reversal of p15/INK4b hypermethylation in AML1/ETO-positive and -negative myeloid leukemia cell lines.
Berg T; Guo Y; Abdelkarim M; Fliegauf M; Lübbert M
Leuk Res; 2007 Apr; 31(4):497-506. PubMed ID: 17056112
[TBL] [Abstract][Full Text] [Related]
3. PML-RARalpha and AML1-ETO translocations are rarely associated with methylation of the RARbeta2 promoter.
Tabe Y; Konopleva M; Kondo Y; Contractor R; Jin L; Ruvolo V; Tsutsumi-Ishii Y; Miyake K; Miyake N; Ohsaka A; Nagaoka I; Issa JP; Andreeff M
Ann Hematol; 2006 Oct; 85(10):689-704. PubMed ID: 16832676
[TBL] [Abstract][Full Text] [Related]
4. Inhibitors of DNA methylation and histone deacetylation independently relieve AML1/ETO-mediated lysozyme repression.
Claus R; Fliegauf M; Stock M; Duque JA; Kolanczyk M; Lübbert M
J Leukoc Biol; 2006 Dec; 80(6):1462-72. PubMed ID: 17000900
[TBL] [Abstract][Full Text] [Related]
5. Epigenetic-based treatments emphasize the biologic differences of core-binding factor acute myeloid leukemias.
Serrano E; Carnicer MJ; Lasa A; Orantes V; Pena J; Brunet S; Aventín A; Sierra J; Nomdedéu JF
Leuk Res; 2008 Jun; 32(6):944-53. PubMed ID: 18206229
[TBL] [Abstract][Full Text] [Related]
6. AML1/ETO-induced survivin expression inhibits transcriptional regulation of myeloid differentiation.
Balkhi MY; Christopeit M; Chen Y; Geletu M; Behre G
Exp Hematol; 2008 Nov; 36(11):1449-60. PubMed ID: 18687517
[TBL] [Abstract][Full Text] [Related]
7. Inhibitors of histone deacetylase relieve ETO-mediated repression and induce differentiation of AML1-ETO leukemia cells.
Wang J; Saunthararajah Y; Redner RL; Liu JM
Cancer Res; 1999 Jun; 59(12):2766-9. PubMed ID: 10383127
[TBL] [Abstract][Full Text] [Related]
8. AML1-ETO downregulates the granulocytic differentiation factor C/EBPalpha in t(8;21) myeloid leukemia.
Pabst T; Mueller BU; Harakawa N; Schoch C; Haferlach T; Behre G; Hiddemann W; Zhang DE; Tenen DG
Nat Med; 2001 Apr; 7(4):444-51. PubMed ID: 11283671
[TBL] [Abstract][Full Text] [Related]
9. The fusion protein AML1-ETO in acute myeloid leukemia with translocation t(8;21) induces c-jun protein expression via the proximal AP-1 site of the c-jun promoter in an indirect, JNK-dependent manner.
Elsässer A; Franzen M; Kohlmann A; Weisser M; Schnittger S; Schoch C; Reddy VA; Burel S; Zhang DE; Ueffing M; Tenen DG; Hiddemann W; Behre G
Oncogene; 2003 Aug; 22(36):5646-57. PubMed ID: 12944913
[TBL] [Abstract][Full Text] [Related]
10. New mechanisms of AML1 gene alteration in hematological malignancies.
Roumier C; Fenaux P; Lafage M; Imbert M; Eclache V; Preudhomme C
Leukemia; 2003 Jan; 17(1):9-16. PubMed ID: 12529654
[TBL] [Abstract][Full Text] [Related]
11. The AML1 gene: a transcription factor involved in the pathogenesis of myeloid and lymphoid leukemias.
Lo Coco F; Pisegna S; Diverio D
Haematologica; 1997; 82(3):364-70. PubMed ID: 9234595
[TBL] [Abstract][Full Text] [Related]
12. ELA2 is regulated by hematopoietic transcription factors, but not repressed by AML1-ETO.
Lausen J; Liu S; Fliegauf M; Lübbert M; Werner MH
Oncogene; 2006 Mar; 25(9):1349-57. PubMed ID: 16247445
[TBL] [Abstract][Full Text] [Related]
13. Rearrangements of the AML1/CBFA2 gene in myeloid leukemia with the 3;21 translocation: in vitro and in vivo studies.
Zent C; Rowley JD; Nucifora G
Leukemia; 1997 Apr; 11 Suppl 3():273-8. PubMed ID: 9209363
[TBL] [Abstract][Full Text] [Related]
14. Transcription of the AML1/ETO chimera is guided by the P2 promoter of the AML1 gene in the Kasumi-1 cell line.
Markova EN; Kantidze OL; Razin SV
Gene; 2012 Dec; 510(2):142-6. PubMed ID: 22995345
[TBL] [Abstract][Full Text] [Related]
15. The t(8;21) fusion protein, AML1 ETO, specifically represses the transcription of the p14(ARF) tumor suppressor in acute myeloid leukemia.
Linggi B; Müller-Tidow C; van de Locht L; Hu M; Nip J; Serve H; Berdel WE; van der Reijden B; Quelle DE; Rowley JD; Cleveland J; Jansen JH; Pandolfi PP; Hiebert SW
Nat Med; 2002 Jul; 8(7):743-50. PubMed ID: 12091906
[TBL] [Abstract][Full Text] [Related]
16. Repression of vascular endothelial growth factor expression by the runt-related transcription factor 1 in acute myeloid leukemia.
Ter Elst A; Ma B; Scherpen FJ; de Jonge HJ; Douwes J; Wierenga AT; Schuringa JJ; Kamps WA; de Bont ES
Cancer Res; 2011 Apr; 71(7):2761-71. PubMed ID: 21447743
[TBL] [Abstract][Full Text] [Related]
17. Specific protein redirection as a transcriptional therapy approach for t(8;21) leukemia.
Steffen B; Serve H; Berdel WE; Agrawal S; Linggi B; Büchner T; Hiebert SW; Müller-Tidow C
Proc Natl Acad Sci U S A; 2003 Jul; 100(14):8448-53. PubMed ID: 12819347
[TBL] [Abstract][Full Text] [Related]
18. Selective anti-leukaemic activity of low-dose histone deacetylase inhibitor ITF2357 on AML1/ETO-positive cells.
Barbetti V; Gozzini A; Rovida E; Morandi A; Spinelli E; Fossati G; Mascagni P; Lübbert M; Dello Sbarba P; Santini V
Oncogene; 2008 Mar; 27(12):1767-78. PubMed ID: 17891169
[TBL] [Abstract][Full Text] [Related]
19. A distinct epigenetic signature at targets of a leukemia protein.
Rossetti S; Hoogeveen AT; Liang P; Stanciu C; van der Spek P; Sacchi N
BMC Genomics; 2007 Feb; 8():38. PubMed ID: 17266773
[TBL] [Abstract][Full Text] [Related]
20. Williams-Beuren syndrome critical region-5/non-T-cell activation linker: a novel target gene of AML1/ETO.
Fliegauf M; Stock M; Berg T; Lübbert M
Oncogene; 2004 Dec; 23(56):9070-81. PubMed ID: 15489901
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
